Point72 Asset Management L.P. Raises Position in Zimmer Biomet Holdings Inc (ZBH)

Point72 Asset Management L.P. boosted its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 0.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 697,900 shares of the medical equipment provider’s stock after acquiring an additional 4,200 shares during the period. Point72 Asset Management L.P. owned 0.34% of Zimmer Biomet worth $81,717,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ingalls & Snyder LLC grew its stake in Zimmer Biomet by 2.6% in the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after acquiring an additional 507 shares during the last quarter. Koch Industries Inc. grew its stake in Zimmer Biomet by 49,697.3% in the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after acquiring an additional 1,038,674 shares during the last quarter. Jensen Investment Management Inc. grew its stake in Zimmer Biomet by 24.2% in the 2nd quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock valued at $751,000 after acquiring an additional 1,140 shares during the last quarter. Andra AP fonden grew its stake in Zimmer Biomet by 15.8% in the 2nd quarter. Andra AP fonden now owns 21,300 shares of the medical equipment provider’s stock valued at $2,735,000 after acquiring an additional 2,900 shares during the last quarter. Finally, Commerce Bank grew its stake in Zimmer Biomet by 1.5% in the 2nd quarter. Commerce Bank now owns 218,171 shares of the medical equipment provider’s stock valued at $28,013,000 after acquiring an additional 3,142 shares during the last quarter. 86.24% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have issued reports on ZBH shares. Deutsche Bank raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research note on Tuesday, November 14th. Zacks Investment Research cut shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, November 20th. Edward Jones raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Thursday, November 9th. SunTrust Banks set a $136.00 price target on shares of Zimmer Biomet and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Finally, Royal Bank Of Canada decreased their price target on shares of Zimmer Biomet to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 7th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $133.71.

Shares of Zimmer Biomet Holdings Inc (ZBH) traded down $1.40 during mid-day trading on Monday, hitting $113.38. 1,680,500 shares of the stock traded hands, compared to its average volume of 1,356,293. The stock has a market cap of $22,956.40, a price-to-earnings ratio of 14.05, a P/E/G ratio of 1.76 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 1-year low of $100.81 and a 1-year high of $133.49. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company’s revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.79 earnings per share. equities analysts expect that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Point72 Asset Management L.P. Raises Position in Zimmer Biomet Holdings Inc (ZBH)” was originally published by Week Herald and is owned by of Week Herald. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://weekherald.com/2017/12/11/point72-asset-management-l-p-raises-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply